PCOS Assessment — Rotterdam Criteria 2023
Comprehensive PCOS screening covering ovulatory dysfunction, clinical hyperandrogenism (Modified Ferriman-Gallwey Score, Ludwig Scale, GAGS Score, Acanthosis Nigricans), biochemical hyperandrogenism (Free Testosterone, Free Androgen Index), and polycystic ovarian morphology (transvaginal ultrasound, follicle counts).
PCOS Assessment
Note on the name: in May 2026, polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS) following a global consensus process. The old name was inaccurate — the condition affects multiple hormone and metabolic systems, not just the ovaries, and 'polycystic' wrongly implies ovarian cysts. Nothing about the condition, its diagnosis or its treatment has changed. We use PCOS below as the term most people know. This assessment screens for Polycystic Ovary Syndrome (PCOS) using the internationally validated Rotterdam 2023 criteria. Diagnosis requires any 2 of 3 criteria: ovulatory dysfunction, hyperandrogenism, or polycystic ovarian morphology.
Reference: International Evidence-Based Guideline for PCOS, ASRM/ESHRE 2023
Criterion 1
Ovulatory Dysfunction
Irregular or absent periods
Criterion 2
Hyperandrogenism
Clinical signs or blood tests
Criterion 3
PCOM on Ultrasound
≥20 follicles per ovary
Diagnosis requires any 2 of 3 criteria
This assessment takes approximately 8–12 minutes. You will be shown clinical illustrations and photographs to help you accurately score each symptom. All data is encrypted.